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Abstract 
 
Myc family proteins promote cancer by inducing widespread changes in gene 
expression. Their rapid turn-over by the ubiquitin-proteasome pathway is regulated 
through phosphorylation of Myc Box I and ubiquitination by SCFFbxw7. However, N-
Myc protein is stabilized in neuroblastoma by Aurora-A kinase in a manner that is 
sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction 
between the catalytic domain of Aurora-A and a site flanking Myc Box I that also 
binds SCFFbxw7. We determine the crystal structure of the complex between Aurora-A 
and this region of N-Myc to 1.72 Å resolution. The structure indicates that the 
conformation of Aurora-A induced by compounds such as alisertib and CD532 is not 
compatible with binding of N-Myc, explaining the activity of these compounds in 
neuroblastoma cells and providing a rational basis for the design of cancer 
therapeutics optimized for destabilization of the complex. We also propose a model 
for the stabilization mechanism in which binding to Aurora-A alters how N-Myc 
interacts with SCFFbxw7 to disfavor the generation of Lys48-linked poly-Ub chains. 
 
 
Significance 
  
 Elevated levels of N-Myc protein drives cancers such as neuroblastoma. 
Accumulation of N-Myc in these cancer cells depends upon the formation of a 
complex with Aurora-A kinase in which the N-Myc is not properly degraded. We 
mapped the region of N-Myc that interacts with Aurora-A and determined the 
molecular structure of the complex. Since this region also interacts with cellular 
machinery that targets N-Myc for degradation, we also seek to provide insights into 
the mechanism of stabilization of N-Myc by Aurora-A. The structure also explains 
how compounds that induce distorted conformations of Aurora-A are able to disrupt 
the interaction with N-Myc and may provide a basis for designing better compounds 
that work in this way for treatment of neuroblastoma. 
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/body 
Introduction  
 
Myc proteins are transcription factors that markedly alter gene expression 
through both activation and repression of transcription (1, 2). Three Myc protein 
family members can be aberrantly expressed in human cancers. c-Myc (Myc) was 
first discovered as the cellular homologue of the viral v-Myc oncoprotein and is 
frequently deregulated in a wide range of human cancers (3-5).  N-Myc (MYCN) and 
L-Myc (MYCL) were subsequently identified as the products of amplified genes in 
neuroblastoma and small cell lung cancer, respectively (6-8). Inhibition of Myc is a 
validated therapeutic strategy, but efforts to develop clinical compounds that target 
Myc proteins directly have failed (9). 
 
c-Myc, N-Myc and L-Myc have regions of sequence homology that mediate 
interactions with critical partner proteins such as Max, WDR5, TRRAP, PAF1C and 
Aurora-A (10). The most C-terminal of these regions forms an essential DNA-binding 
domain through formation of a basic helix-loop-helix leucine zipper domain in 
complex with Max (9, 11). Other conserved sequence motifs called Myc boxes (MB0-
IV) serve as docking sites for protein-protein interactions (10, 12, 13). The Myc 
transactivation domain (TAD), spans the N-terminal conserved motifs MB0, MBI and 
MBII.   The TAD of c-Myc is intrinsically disordered, as reported by circular dichroism 
and nuclear magnetic resonance spectroscopy, but there are transient secondary 
structure elements that, in some cases, become stable in complex with binding 
partners (12, 14, 15).  
 
The stability of Myc proteins is regulated by phosphorylation within MBI, 
which targets the protein for ubiquitinylation and proteolysis. For example, N-Myc is 
first phosphorylated on Ser62 by Cdk1/cyclin B, then phosphorylated on Thr58 by 
Gsk3b (16). Dephosphorylation of Ser62 by PP2A directs the activity of the E3 
ubiquitin ligase SCFFbxw7 to modify N-Myc with K48-linked ubiquitin chains (17, 18). In 
neuroblastoma cells, the Ser/Thr protein kinase Aurora-A blocks this process, 
resulting in an excess of N-Myc protein (19). Aurora-A binds to the N-Myc/SCFFbxw7 
complex, and reduces the proportion of K48 linkages in the poly-ubiquitin chains. 
Catalytic activity of Aurora-A is not required for N-Myc stabilization, and the 
underlying mechanism is unclear.  Some Aurora-A inhibitors such as 
MLN8237/alisertib and CD532 can destabilize N-Myc by disrupting the complex, 
whilst other Aurora-A inhibitors have no effect (19, 20).  The current hypothesis is 
	 4	
that the destabilizing inhibitors alter the conformation of Aurora-A in ways that disrupt 
the complex, whereas inhibitors that compete with ATP without causing a 
conformational change leave the complex intact (20-22).  
 
We set out to investigate the structural basis of Aurora-A stabilization of N-
Myc and the effect of Aurora-A inhibitors on the complex. Here we show that the 
catalytic domain of Aurora-A interacts directly with N-Myc through binding sites that 
flank either side of MBI. We present a crystal structure of the complex between 
Aurora-A and a fragment of N-Myc corresponding to the region immediately C-
terminal to MBI which reveals Aurora-A in a fully active conformation that is 
incompatible with inhibitors of Aurora-A that disrupt the complex. Biochemical studies 
show an interaction between SCFFbxw7 and the same region of N-Myc and we 
propose that the way in which Aurora-A interferes with this interaction changes N-
Myc ubiquitination to promote stability. 
 
 
Results and Discussion 
 
Structural basis of the interaction between N-Myc and Aurora-A. To show that 
Aurora-A and N-Myc interact directly, we carried out a co-precipitation experiment 
using a GST-Aurora-A kinase domain fusion protein incubated with a range of 
purified fragments from the N-Myc TAD (Fig. S1A). This method identified residues 
28-89 of N-Myc as the minimal Aurora-A-interaction region (AIR), which spans from 
MB0, through MBI but does not include MBII or beyond (Fig. 1A). The binding affinity 
of Aurora-A for the AIR was quantified as 2.9 μM ±0.5 by ELISA (Fig. S1B) and 1.0 
μM ±0.3 by competition AlphaScreen™ assay (Fig. 1B). The presence of a 
tryptophan residue towards the C-terminus of this N-Myc fragment was striking, and 
mutation of Trp88 to alanine abrogated the interaction in the context of the entire N-
Myc TAD fragment (residues 1-137) in a precipitation experiment with GST-tagged 
Aurora-A catalytic domain (residues 122-403); the TAD of N-Myc did not interact with 
GST alone and, together, these results indicate that the interaction is specific (Fig. 
S1C). 
To elucidate the structural basis of the Aurora-A/N-Myc interaction, we 
crystallized a complex between the Aurora-A kinase domain, with surface cysteines 
mutated to enhance stability (Aurora-AC290A/C393A), with a synthetic N-Myc peptide 
corresponding to residues 28-89. The crystals yielded diffraction data to 1.72 Å 
resolution and we solved the structure by molecular replacement using an existing 
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structure of Aurora-AC290A/C393A (Table S1 and Fig. S1D). Residues 28-60 of N-Myc 
are not observed in the structure while residues 61-89 are associated with the cleft 
between the N- and C- lobes of the Aurora-A kinase domain formed by the αB/αC 
helices, activation loop and αG helix (Fig. 1C). N-Myc residues 76-89 form an α-helix, 
which packs onto the C-lobe of Aurora-A at a surface formed by Tyr334, Gln335 and 
Tyr338 with its N-terminus pointing towards the substrate-binding region. Both ends 
of the α-helix are capped by tryptophan residues (Trp77 and Trp88) whose 
sidechains pack against the surface of Aurora-A. Key intermolecular interactions 
include a salt-bridge between Glu73 of N-Myc and Lys143 from the Gly-rich loop on 
the N-lobe of Aurora-A, a further interaction between Gln335 of Aurora-A and Trp88 
of N-Myc and the insertion of the Trp77 sidechain of N-Myc into the hydrophobic P+1 
pocket in the activation loop region of Aurora-A (Fig. 1D). A pair of prolines (P74 and 
P75) break the α-helix at its N-terminus and directs the chain towards the Aurora-A 
N-lobe. Residues 69-71 are hydrogen-bonded into a turn and residues 61-67 are 
bound into a groove between the N-lobe and the surface formed by the activation 
loop. 
 
The region of N-Myc observed in the crystal structure starts at the C-terminus 
of MBI, and is not conserved in c-Myc (Fig. S2A). Our initial mapping suggested that 
this region was insufficient for binding, so we used a more sensitive assay, based on 
changes in fluorescence polarization (FP) using synthetic peptides of N-Myc, to 
confirm that residues 61-89 of N-Myc bind Aurora-A independently, with a measured 
Kd of 12 μM (Fig. S2B). N-Myc peptides with E73K or W77A mutations reduced 
binding to Aurora-A, consistent with their observed contributions to the interface in 
the crystal structure (Fig. S2B). Similarly, the contributions of Aurora-A Y334 and 
Q335 to the interaction were confirmed.  
The section of the AIR that was not resolved in the crystal structure, residues 
28-60 of N-Myc, includes the MB0 and MBI regions and is conserved in c-Myc (Fig. 
S2A).  Having shown that the C-terminal part of the AIR was able to bind Aurora-A 
independently, we looked for further sub-fragments that might contribute to binding 
with a sensitive pull-down assay using peptides spanning the region, under less 
stringent conditions than the first set of pull-downs used for mapping the interaction 
(Fig. S2C). In addition to residues 61-89, a region corresponding to MB0 was also 
capable of independent interaction with Aurora-A. Using the FP assay, we confirmed 
that a peptide spanning residues 19-47 of N-Myc, including MB0, binds 
independently to Aurora-A (Fig. S2D). The presence of conserved aromatic residues 
in this region is striking (F28, Y29, F35, Y36), and these were shown to contribute to 
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the interaction with Aurora-A (Fig. S2D). In contrast to the established roles of the 
regions flanking it, MBI itself does not appear to contribute to the interaction with 
Aurora-A because a peptide corresponding to residues 44-64 showed no binding in 
the peptide co-precipitation assay (Fig. S2C). Consistent with this, neither the 
phosphorylation status of the phosphodegron residues Thr58 and Ser62, nor 
mutation of residues 52-56 to alanine, affected Aurora-A binding of the N-Myc 28-89 
peptide (Fig. S2E). We postulate that the flanking regions either side of MBI form 
specific interactions with Aurora-A, linked by the MBI region itself, which interacts in 
a phosphorylation-dependent manner with FbxW7, but makes no critical interactions 
with Aurora-A. 
 
The interaction of N-Myc activates Aurora-A and competes with TPX2. When 
bound to N-Myc, Aurora-A is in a fully active conformation, similar to that observed 
for the Aurora-A/TPX2 complex (Fig. 2A) (23). TPX2 binds to Aurora-A through its 
first 43 residues: aa7-21 at a site on the N-lobe and aa30-43 at a site between the 
two lobes. The conformation adopted by Aurora-A when bound to TPX2 is 
incompatible with the interaction of N-Myc residues 61-67 (Fig. 2B). Most clearly, 
there is a steric clash because Leu61 of N-Myc binds to the same pocket on the 
Aurora-A surface as Trp34/Phe35 of TPX2. To accommodate the marked increase in 
size in going from the single Leu side chain of N-Myc to the two bulky side chains of 
TPX2, the side chain of Aurora-A residue His187 rotates out of the pocket in the 
TPX2-bound conformation.  Side chains on the αC-helix of Aurora-A such as His176 
and Arg179, are also observed in different positions, suggesting that the N-terminal 
stretch of TPX2 (Tyr8/Tyr10) that binds on one side of the αC-helix is incompatible 
with binding of N-Myc to the other side of the αC-helix. Consistent with this structural 
analysis, the first 43 amino acids of TPX2 and the AIR of N-Myc compete for binding 
to Aurora-A (Fig 2C) and they also have comparable affinities, since Kd values of 2-3 
μM were measured for both proteins in ELISA assays using immobilized Aurora-A 
(Fig. S1B).  Competition with TPX2 was observed for the individual regions of the 
AIR both N- and C- terminal to MB1 (Fig. 2C) suggesting that the binding site for 
MB0 on Aurora-A also overlaps with that of TPX2. The AIR of N-Myc, like TPX2, 
activates initially unphosphorylated Aurora-A, and so there is also functional overlap 
between these two Aurora-A binding proteins (Fig. 2D, Fig. S3). The crystal structure 
reported here does not reveal the mechanism by which N-Myc activates Aurora-A 
because residues 61-89 of N-Myc were not sufficient to activate Aurora-A, and we 
used Aurora-A pre-phosphorylated on Thr288 to form the complex. However, it is 
clear that N-Myc, like TPX2, is able to trigger Aurora-A activation through protein-
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protein interactions, and the result is a stabilized conformation of Aurora-A in which 
the activation loop forms a platform for the binding of N-Myc residues 61-89 (Fig. 2E). 
Furthermore, as shown in Fig. S3, Aurora-A is able to efficiently phosphorylate 
residues within the 28-89 region of N-Myc in vitro. 
 
The conformation of Aurora-A bound to N-Myc is incompatible with inhibitors 
that destabilize the interaction. Previous studies showed that ATP-competitive 
inhibitors of Aurora-A such as MLN8054, MLN8237 and CD532 disrupt Aurora-A/N-
Myc complex formation, resulting in destabilization of N-Myc in cell models. Crystal 
structures of Aurora-A in complex with MLN8054 or CD532 show distorted 
conformations of the kinase, notably in the positions of the activation loop and Gly-
rich loop (20, 21). In contrast, most Aurora-A inhibitors, such as CCT137690, do not 
substantially affect the structure of the protein (24). There is no available crystal 
structure of MLN8237 bound to Aurora-A, but the chemical structures of MLN8054 
and MLN8237 are almost identical and it is likely that MLN8237 induces a similar 
conformation in Aurora-A.  We compared the structures of Aurora-A in complex with 
N-Myc, MLN8054, CD532 and CCT137690 (Fig. 3A). Aurora-A grips N-Myc through 
interactions involving both N- and C-lobes of the kinase (colored orange in Fig. 3A). 
Binding of CCT137690 does not affect the relative orientation of the two kinase lobes. 
The activation loop of Aurora-A is disordered in the Aurora-A/CCT137690 structure 
because it is neither phosphorylated nor stabilized by a protein such as TPX2 or N-
Myc, and there is no obvious mechanism by which CCT137690 could affect the 
activation loop. However, when bound to MLN8054 or CD532, the surfaces that form 
the binding site for residues 61-89 of N-Myc are moved apart through motions that 
twist the two kinase lobes relative to one another and displace the activation loop 
(Fig. 3B). The rearrangement of this binding site provides a possible mechanism by 
which compounds like MLN8054 disrupt the Aurora-A/N-Myc complex by acting as a 
‘wedge’ that forces the kinase into an inactive conformation. The key differences 
between CCT137690 and MLN8054 are that only the latter makes a specific contact 
with the displaced activation loop and, while both compounds contact both the hinge 
and the Gly-rich loop, the ‘wedge’ effect is a function of the three-dimensional shape 
of MLN8054 in contrast to the flatter scaffold of CCT137690.  
 
Consistent with the structural analysis, MLN8054 but not CCT137690 
disrupted the direct interaction of the catalytic domain of Aurora-A with its binding 
sites within the AIR (Fig. 3C). Indeed, Aurora-A bound to MLN8054 displayed 2-3-
fold reduced affinity for both of the binding sites within the AIR of N-Myc compared to 
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Aurora-A alone Fig. S4). Next, we used proximity ligation assays to quantify complex 
formation between endogenous N-Myc and Aurora-A proteins in a neuroblastoma 
cell-line (Fig. 3D,E) and observed significantly fewer interactions in cells treated with 
MLN8054 or MLN8237 than in untreated cells while the number of interactions was 
unaffected by treatment with CCT137690. 
 
A model for the regulation of N-Myc ubiquitination by Aurora-A. In this study, we 
showed that Aurora-A binds N-Myc irrespective of its phosphorylation state, and 
interacts with regions of N-Myc that flank MBI. The binding interaction between the 
Aurora-A catalytic domain and N-Myc residues 61-89 that we have resolved is 
immediately adjacent to the phospho-degron motif centered on Thr58, 
phosphorylation of which is required for recognition of N-Myc by SCFFbxW7.  Thus, 
binding of Aurora-A might affect the interaction of N-Myc with SCFFbxW7. Using 
purified proteins, we discovered that SCFFbxw7, like Aurora-A, interacts with N-Myc 
irrespective of the phosphorylation state of Thr58/Ser62 (Fig. 4A). Binding of 
SCFFbxw7 to N-Myc that is phosphorylated on Thr58/Ser62 was not affected by 
Aurora-A, consistent with non-overlapping binding sites on N-Myc. In contrast, the 
binding of SCFFbxw7 to unphosphorylated N-Myc was competed by Aurora-A. This 
observation suggested that the interaction of SCFFbxw7 with unphosphorylated N-Myc 
might depend on a binding site that overlaps with one or both of the Aurora-A binding 
sites that flank MBI. Binding of SCFFbxw7 was mapped to residues 61-89 of N-Myc 
and binding was also observed to residues 48-89 of N-Myc, but an unphosphorylated 
MBI peptide (residues 44-64) did not bind (Fig. 4B).  Aurora-A efficiently competed 
with SCFFbxw7 for binding to residues 48-89 of N-Myc, in a dose-dependent manner, 
whereas a control protein (bovine serum albumin) did not compete (Fig. 4C). Taken 
together, these results show that there is competition between Aurora-A and 
SCFFbxw7 for binding to residues 61-89 of N-Myc, the region bound to Aurora-A in the 
crystal structure. 
 
These observations suggest a working model by which Aurora-A could stabilize N-
Myc through altering its interaction with SCFFbxw7 , which we put forward as a basis for 
further investigation (Fig. 4D).  Recruitment of N-Myc to SCFFbxw7 is driven by the 
well-characterized interaction between the phospho-degron and FbxW7 that is 
regulated by phosphorylation of Thr58. However, a second interaction is also formed 
between N-Myc residues 61-89 and an unknown site on SCFFbxw7. Aurora-A binds to 
N-Myc at sites that flank the phospho-degron, disrupting the interaction between 
residues 61-89 of N-Myc and SCFFbxw7 , but not the phospho-degron region, and so a 
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complex of Aurora-A, N-Myc and SCFFbxw7 is formed. We postulate that the 
interaction between N-Myc residues 61-89 and SCFFbxw7 is important for efficient 
polyubiquitination of N-Myc, and that disruption of this interaction by Aurora-A 
reduces the formation of Lys48-linked chains on N-Myc, as previously reported (19).  
 
The dysregulation of Myc proteins is a feature of several cancers that are refractory 
to treatment and targeting Myc is a validated therapeutic strategy (9, 25-27). 
Unfortunately, there are currently no drug-like molecules that target Myc directly. Myc 
family proteins are intrinsically disordered proteins that dynamically adopt many 
conformations and, therefore, lack “druggable” pockets. This property has frustrated 
attempts to develop a drug-like molecule that directly targets the interaction of Myc 
with its binding partners. Here, we have characterized the complex with Aurora-A in 
which N-Myc is trapped in an ordered conformation. Disruption of the interaction can 
be achieved by targeting the ATP binding site of Aurora-A to induce a conformation 
that is incompatible with the binding of N-Myc, and early clinical trial data suggests 
these compounds may provide patient benefit when combined with chemotherapy 
(20, 22, 28). However, this approach would also target the main function of Aurora-A 
in the proper assembly and function of the mitotic spindle, and it is too early to know 
whether the potential benefit of this in targeting dividing cancer cells offsets the 
accompanying damage to normal tissue. Alternatively, it may be possible to inhibit 
the protein-protein interaction directly by targeting the interface. The structure of the 
Aurora-A/N-Myc complex provides a rational basis for the development of inhibitors 
that destabilize N-Myc and molecular coordinates of the interface that will facilitate 
structure-guided approaches to target the binding sites for ATP or N-Myc on Aurora-
A. 
 
Materials and Methods 
 
Crystallography. Aurora-A 122-403 containing the mutations C290A and C393A 
was expressed and purified as described previously (29) and gel-filtrated into 20 mM 
Tris pH 7.5, 200 mM NaCl, 5 mM MgCl2, 5 mM β-mercaptoethanol and 10% glycerol. 
An N-biotinyl peptide corresponding to residues 28-89 of N-Myc and carrying a 
phosphothreonine at position 58 (Peptide Synthetics) was dissolved to 10 mM in 
dimethylsulfoxide (DMSO). A mixture containing 300 μM Aurora-A, 5 mM adenosine 
diphosphate and 500 μM N-Myc peptide (with a final DMSO concentration of 5%) 
was incubated on ice for 1 h and then mixed 1:1 with reservoir solution (100 mM 
Bicine pH 9.0, 20% PEG 6000). Crystals were obtained by vapour diffusion at 18 °C 
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within a few days and were frozen in reservoir solution supplemented with 25% 
ethylene glycol. Diffraction data was collected from a single crystal at Diamond I03 
and processed with xia2 (30) (Table S1). The structure of the Aurora-A/N-Myc 
complex was solved by molecular replacement phasing using Phaser (31) with an 
existing Aurora-A structure (PDB 4CEG) (29) as the search model. Iterative 
modelling and refinement was carried out using Coot (32) and phenix.refine (33). 
Structure validation was carried out using Molprobity (34). Crystallographic data, 
refinement statistics and details of structure validation analysis are summarized in 
Table S1. Structure figures were prepared using PyMOL (http://www.pymol.org). 
 
Co-precipitation assay. For in vitro peptide co-precipitation assays, 40 μL of 
Streptactin Sepharose beads (IBA) were incubated with 900 μL of 10 μM N-biotinyl 
N-Myc peptides for 1 hour and then washed 3 times with pull-down buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM β-mercaptoethanol, 0.02% Tween-20). 
The beads were then incubated with 900 μL of a solution containing analyte proteins, 
competing proteins or compounds as required, for 2 hours at 4 °C and then washed 
3 times with 900 μL pull-down buffer. Finally, the beads were eluted by boiling with 
80 μL SDS-loading buffer and the eluted proteins analysed by SDS-PAGE. Aurora-A 
122-403 was used at a final concentration of 12 μM. SCFFbxW7 incorporating GST-
tagged FbxW7 (Millipore) was used at a final concentration of 5.5 ng/μL and 
visualised in precipitates by Western blotting using an anti-GST antibody (GE 
Healthcare).  
 
Competition AlphaScreenª assay. Biotinyl Avi-tagged Aurora-A 122-403 was 
produced as described previously (35). Appropriate concentrations of biotinyl Aurora-
A 122-403 and 3xFlag-N-Myc 28-89 for use in competition experiments were 
determined in preliminary cross-titration experiments over a 0-300 nM range. The 
assay buffer was 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM β-
mercaptoethanol, 0.02% Tween-20 & 0.1% BSA. For competition assays, 10 nM 
biotinyl Aurora-A 122-403, 0.3 nM 3xFlag-N-Myc 28-89 and 0-160 μM Aurora-A 122-
403 were mixed together and incubated at room temperature (RT) for 1 hour in white, 
opaque 96-well ½ area plates. 20 μg/mL streptavidin donor beads and anti-Flag 
acceptor beads (PerkinElmer) were added simultaneously to each reaction under 
subdued lighting conditions and the plate incubated for a further 90 minutes. The 
signal from each reaction was read using an EnVision multilabel plate-reader 
(PerkinElmer). Data-points represent the mean of three experiments; error bars 
indicate SD. Data were analysed using Graphpad Prism 6 and the dependence of 
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the AlphaScreen™ signal on the concentration of competing Aurora-A 122-403 was 
fitted by non-linear regression to a one-site logIC50 equation where, under the 
selected reaction conditions, IC50 approximates Kd. Results are reported as Kd ±SE. 
 
In situ proximity ligation assay. Kelly cells were cultured in RPMI 1640 
supplemented with heat-inactivated fetal bovine serum.  500 nM compounds (as 
indicated) were added 4 hours prior to fixation. Cells were fixed with 4% 
paraformaldehyde for 30 minutes and permeablized with phosphate buffered saline 
containing 0.2% Triton X-100 for a further 30 minutes. Cells were incubated with with 
Duolink In situ blocking solution for 1 hour and then with antibodies against Aurora-A 
(Genetex) and N-Myc (Calbiochem) diluted into the same buffer for a further hour. In 
situ proximity ligation assays were carried out using the Duolink kit (Olink Bioscience) 
according to the manufacturers instructions. Images were collected and analysed 
using a Humphrey 730 field analyser system (Zeiss). The average number of 
interactions detected per cell was calculated and results are reported as the mean of 
three independent experiments ±SD. 
 
Kinase assay. 32P-ATP kinase assays were performed as described with 
modifications as follows (36). Measurement of Aurora-A activity was carried out using 
reactions containing 0.625 μM dephosphorylated Aurora-A catalytic domain, 40 μM 
myelin basic protein (Sigma) and 0-50 μM N-Myc 28-89, N-Myc 61-89 or TPX2 1-43 
peptides. Reactions were incubated at 21 °C for 45 minutes and total incorporation of 
32P radioisotope into Aurora-A, N-Myc 28-89 and myelin basic protein was then 
measured by scintillation counting. Results are the mean of two independent 
experiments ±SE.  
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Figure legends 
 
Fig. 1. Crystal structure of Aurora-A/N-Myc complex. (A) Domain structure of N-
Myc with conserved regions indicated as boxes and the Aurora-A Interaction Region 
(AIR) marked with a red line. (B) Quantification of the binding affinity between 
Aurora-A kinase domain and the N-Myc AIR by competition AlphaScreen assay. 
Data represents the mean of three experiments ±SD.  (C) Crystal structure of Aurora-
AC290A/C393A catalytic domain (AurA, green cartoon) in complex with N-Myc residues 
61-89 (N-Myc, red cartoon). (D) Magnified view of the structure with key residues 
shown as sticks. 
 
Fig. 2. Structural and functional comparison of Aurora-A interactions with N-
Myc and TPX2. (A) Superposition of crystal structures of Aurora-A bound to N-Myc 
(colored red) and TPX2 (colored pink). Aurora-A bound to TPX2 is colored a lighter 
shade of green. (B) Magnified view of the superposed structures. The side-chain 
motions accompanying the transition from the N-Myc to the TPX2 complex are 
marked with black arrows. (C) Co-precipitation experiments to investigate 
competition between TPX2 (residues 1-43) and N-Myc fragments for binding to 
Aurora-A (residues 122-403), analysed by SDS-PAGE. The gel shows proteins co-
precipitated with biotinyl-N-Myc peptides (as indicated) immobilized on streptavidin 
beads following incubation with 12 μM Aurora-A catalytic domain in the presence or 
absence of a 5-fold molar excess of TPX2 1-43 protein. (D) Kinase assays to 
measure the activity of 0.625 μM initially unphosphorylated Aurora-A catalytic domain 
in the presence of 32P-ATP and varying concentrations N-Myc peptides (residues 28-
89, 19-47 or 61-89) or TPX2 (residues 1-43), reported by scintillation counting. Data 
are the mean of two experiments ±SE. (E) Schematic illustration of the activating 
interactions of N-Myc and TPX2 with Aurora-A. The unphosphorylated activation loop 
of Aurora-A is flexible (dashed black line) but becomes ordered upon kinase 
activation through binding of protein partners and autophosphorylation.  
 
Fig. 3. The conformation of Aurora-A required for N-Myc binding is 
incompatible with the conformation induced by kinase inhibitors that disrupt 
the interaction. (A) Views of Aurora-A bound to N-Myc (PDB: 5G1X), MLN8054 
(2WTV), CD532 (4J8M) and CCT137690 (2X6E). Key residues of Aurora-A (orange) 
that grasp N-Myc (dark red) remain in place in the presence of CCT137690 but are 
moved apart in the presence of MLN8054/8237 and even further apart in the 
presence of CD532. The dotted line in the rightmost panel indicates the disordered 
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region of the activation loop. (B) Schematic model to explain the disruption of the N-
Myc binding site by ATP-competitive inhibitors. The activation loop is shown in black. 
(C) Competition co-precipitation experiments using untagged Aurora-A catalytic 
domain and biotinylated N-Myc peptides immobilized on streptavidin beads in the 
presence of 20 μM MLN8054 or CCT137690, using 0.2% DMSO as control. (D) 
Incidence of complex formation between N-Myc and Aurora-A observed in situ by 
proximity ligation assay in Kelly neuroblastoma cells treated with compounds as 
indicated.  Data represents mean±SD. No antibodies were added to the control cells. 
(E) Representative images of Kelly cells used in D.  Nuclei are indicated by DAPI 
staining (blue) and red foci indicate the position of Aurora-A/N-Myc complexes. 
 
Fig. 4. Aurora-A alters the interaction of N-Myc with SCFFbxW7. (A) Competition 
co-precipitation experiments using biotinylated N-Myc AIR peptides immobilized on 
streptavidin beads, incubated with 2 μg SCF complex incorporating GST-tagged 
FbxW7 in the presence or absence of 12 μM untagged Aurora-A catalytic domain. 
Binding of SCFFbxW7 to N-Myc was visualized by Western blot (WB) using anti-GST 
antibody. (B) Co-precipitation experiments using biotinylated N-Myc AIR fragment 
peptides immobilized on streptavidin beads and incubated with 2 μg SCF complex 
incorporating GST-tagged FbxW7. Binding of SCFFbxW7 to N-Myc peptides was 
visualized by Western blot using an anti-GST antibody (lower panel). Equal loading 
of resin was assessed by Coomassie staining (upper panel). Note that, despite the 
uneven appearance of the peptides on the upper panel due to differences in 
migration and sensitivity to Coomassie staining, equal amounts were loaded into the 
experiments. (C) Co-precipitation experiments showing competition between 
SCFFbxW7 and Aurora-A for binding to N-Myc 48-89. Biotinylated N-Myc 48-89 peptide 
was immobilized on streptavidin beads and incubated with 2 μg SCFFbxW7 complex in 
the presence of Aurora-A at a range of concentrations, or bovine serum albumin 
(BSA). FbxW7 co-precipitating with the peptide was visualized by anti-GST Western 
blot. (D) A working model to explain how the interaction between Aurora-A and N-
Myc residues 61-89 may reduce ubiquitination to stabilize N-Myc. In this model, a low 
affinity interaction between the 61-89 region and SCFFbxW7 is required for N-Myc to be 
effectively modified with K48-linked polyubiquitin chains and competitive binding of 
Aurora-A to this region interferes with K48-linked polyubiquitination of N-Myc leading 
to reduced proteasomal degradation. 
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Supporting information 
 
SI Methods 
 
Protein production and co-precipitation assay. TPX2 1-43 and GST-Aurora-A 
122-403 D274N were expressed and purified as described previously (Burgess et al., 
2015). Constructs encoding 3xFlag-tagged fragments of the N-Myc transactivation 
domain and TPX-2 1-43 were expressed as His-NusA fusions in Eschericia coli BL21 
(DE3) RIL cells and purified on 5 mL Chelating Sepharose columns (GE Healthcare) 
charged with nickel; the His-NusA tags were cleaved away using tobacco etch virus 
protease and removed by nickel affinity chromatography; the remaining 3xFlag-
tagged polypeptides were further purified by anion exchange on a Resource Q 
column (GE Healthcare) over a 50-500 mM NaCl gradient in 20 mM Tris pH 7.5, 1 
mM EDTA and then by gel filtration into TBS using a Superdex 75 column (GE 
Healthcare). 250 μg GST-Aurora-A 122-403 D274N or 100 μg of GST were 
immobilized on 40 μL of glutathione Sepharose beads (GE Healthcare) and 
incubated with 900 μL of 35 μM 3xFlag-N-Myc fragments (including compounds as 
required) for 2 hours in pull-down buffer. The beads were washed 4 times with 900 
μL pull-down buffer.  Bound proteins were analysed by SDS-PAGE and visualized by 
Coomassie staining and by anti-Flag immunoblotting (M2, Sigma). 
 
 
ELISA assay. Pre-blocked HBC Streptavidin plates (Pierce) were incubated with 10 
μg/mL biotinyl Avi-tagged-Aurora-A 122-403 for 30 minutes at RT. Wells were 
washed 3 times with 300 μL PBS supplemented with 0.1% Tween-20 (PBST).  0-40 
μM 3xFlag-N-Myc 28-89 was added to the wells and incubated for 1 hour at RT. 
Negative control reactions containing no immobilised Aurora-A were also performed. 
Plates were washed with PBST followed by the addition 1:5000 of horse-radish 
peroxidase-conjugated anti-Flag antibody (abcam ab49763). Reactions were 
incubated at RT for a further 30 minutes and washed again with PBST. Binding of 
3xFlag-N-Myc 28-89 was resolved by addition of 3,3’,5,5’-Tetramethylbenzidine and 
the reaction quenched by the addition of 0.5 M H2S04. Absorbance at 450 nm was 
read for each reaction. Data-points represent the mean of three experiments; error 
bars indicate SD. The data were fitted to a one-site specific binding equation by non-
linear regression using Graphpad Prism 6. Results are reported as Kd ±SE. 
 
	 2	
Fluorescence polarization assay. 50 nM fluorescein-labelled N-Myc aa61-89 or 
aa19-47 peptides (Pepceuticals) were incubated at 21 °C with Aurora-A kinase 
domain protein (aa122-403) at a range of concentrations in a buffer containing 
25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5% glycerol, and 0.02% Tween-
20 in a flat-bottomed, black 96-well plate at a total volume of 50 μl per sample. 
Dephosphorylated Aurora-A catalytic domain was made by co-expression with 
lambda phosphatase and purified in the same way as non-dephosphorylated protein 
(Burgess et al., 2015). To investigate the influence of MLN8054 on the interaction, 
the compound was dissolved in DMSO to a concentration of 10 mM and added to a 
final concentration of 600 μM to all samples; an equivalent quantity of DMSO (6%) 
was added to corresponding compound-free samples. Fluorescence polarization was 
measured using a Victor X5 instrument (PerkinElmer) at excitation and emission 
wavelengths of 480 nm and 535 nm. Data-points represent the mean of three 
experiments; error bars indicate SD. The dependence of fluorescence polarization 
upon Aurora-A concentration was fitted to a one-site total binding model by non-
linear regression using GraphPad Prism 6. Results are reported as Kd ±SE. 
 
 
SI Figure Legends 
 
Fig. S1. Interaction between N-Myc and Aurora-A. (A) Co-precipitation of 
fragments of the N-Myc transactivation domain with GST-Aurora-A kinase domain. 
Flag-tagged N-Myc fragments were incubated with GST-Aurora-A 122-403 D274N or 
GST alone immobilised on glutathione Sepharose beads. Co-precipitated N-Myc 
fragments were visualised by anti-Flag Western blot (WB). (B) Binding isotherms 
measured by ELISA quantifying the interaction of 3xFlag-N-Myc 28-89 (upper panel) 
and 3xFlag-N-Myc TPX2 1-43 (lower panel) with immobilised biotinyl Avi-tagged-
Aurora-A 122-403. Data-points represent the mean of three experiments; error bars 
indicate SD. (Affinities of 2.9 μM ± 0.5 and 2.0 ± 0.3 were measured for 3xFlag-N-
Myc 28-89 and 3xFlag-N-Myc TPX2 1-43 respectively.) (C) The specific interaction 
between GST-Aurora-A catalytic domain and Flag-tagged N-Myc TAD is abrogated 
by a single point mutation (Trp88). Glutathione resin precipitates were separated by 
SDS-PAGE followed by Western blot analysis and Coomassie Blue (CB) staining. 
(D) A representative region of the electron density map of the 1.72 Å crystal structure 
of the Aurora-A-N-Myc complex showing the interaction of tryptophan 77 of N-Myc 
(dark red) with a hydrophobic pocket on Aurora-A (pale green). The mesh represents 
a 2mFo-DFc map contoured at 1.0 σ. 
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Fig. S2. Verification of two binding sites for Aurora-A on N-Myc. (A) Sequence 
alignment of N-Myc and c-Myc in the Aurora-A interaction region. Asterisks, colons 
and full stops mark identical, conserved and conservatively substituted residues 
respectively.  Conserved regions MB0 and MBI (incorporating the phospho-degron) 
are boxed and the two binding sites for Aurora-A within N-Myc, corresponding to the 
peptides used in B, are marked with dashed (19-47) and solid (61-89) red lines. (B) 
Binding isotherms measured by fluorescence polarization quantifying the interaction 
between Aurora-A catalytic domain and N-Myc residues 61-89. Data-points represent 
the mean of three experiments; error bars indicate SD. (Affinities of 12.1 μM ±0.6 and 
12.8 μM ±0.7 were measured for binding of the phosphorylated and 
dephosphorylated Aurora-A respectively to wild-type peptide. N-Myc 61-89 peptides 
containing mutations E73K and W77A interacted with wild-type Aurora-A with 
affinities of 81.1 μM ±3.4 and 106 μM ±4.5, respectively. Measured affinities of 
Aurora-A mutants Y334A and Q335A for wild-type N-Myc 61-89 were 22.6 μM ±1.1 
and 16.1 μM ±0.8, respectively.) (C) Co-precipitation experiments showing 
interaction of Aurora-A kinase domain with biotinyl-N-Myc peptides. (Note, some 
peptides do not stain with Coomassie.) (D) Binding isotherms measured by 
fluorescence polarization quantifying the interaction between Aurora-A catalytic 
domain and N-Myc residues 19-47. Data-points represent the mean of three 
experiments; error bars indicate SD. (Affinities of 11.1 μM ±0.4 and 9.2 μM ±0.3 were 
measured for the binding of the phosphorylated and dephosphorylated Aurora-A 
respectively to wild-type N-Myc 19-47 peptide. Affinities of 18.6 μM ±0.6 and 23.7 μM 
±0.8 were measured for the binding of 19-47 peptides containing the mutations F28A 
and F35A respectively, while a peptide containing both of these mutations bound 
with a Kd of 114.0 μM ±4.0. A Y29A, Y36A double mutant 19-47 peptide bound 
Aurora-A with a Kd  of 68.8 μM ±2.3.) (E) Co-precipitation experiments showing 
interaction of Aurora-A kinase domain with biotinyl-N-Myc 28-89 peptides carrying 
different phosphorylation marks within the region corresponding to the phospho-
degron.  52-56_polyA, which is also included in the experiment, is a non-
phosphorylated 28-89 peptide with residues 52-56 mutated to alanine. (The 
sequence of N-Myc in this region 51-KKFELLP-57 bears some resemblance to an 
Aurora-A consensus phosphorylation site (K/R/N-R-XS/T-B), with E54 in place of the 
P1 Ser/Thr. The 28-89 52-56_polyA peptide was used to investigate the possibility 
that a pseudosubstrate interaction between this region of N-Myc and Aurora-A might 
contribute to the binding.) 
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Fig. S3.  Autoradiograph showing activation of Aurora-A by N-Myc 28-89 in the 
presence of 32P-ATP. Initially unphosphorylated full-length Aurora-A shows 
enhanced autophosphorylation in the presence of N-Myc 28-89 peptide. The N-Myc 
peptide also becomes phosphorylated itself. Reactions contained 0.625 μM 
dephosphorylated full-length Aurora-A and 10 μM N-Myc 28-89. Samples were 
separated by SDS-PAGE and 32P-incorporation into individual proteins visualised by 
autoradiography. 
 
Fig. S4. Aurora-A ATP-competitive inhibitors and N-Myc interaction. Binding 
isotherms measured by fluorescence polarization quantifying the interaction of 
Aurora-A catalytic domain (red), and Aurora-A catalytic domain/MLN8054 complex 
(blue), with (A) N-Myc residues 19-47 and (B) N-Myc residues 61-89. Data-points 
represent the mean of three experiments; error bars indicate SD; binding affinities 
between Aurora-A and N-Myc peptides derived from curve-fitting are stated above as 
Kd ±SE. 
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Table S1.  Crystallographic data collection, refinement and structure validation 
statistics.  Values in parentheses refer to the highest resolution shell. 
 AurA/N-Myc complex 
Lattice parameters  
Space group P32 2 1 
Cell dimensions  
    a, b, c (Å) 86.52, 86.52, 92.21 
    α, β, γ)  90.00, 90.00, 120.00 
 
Data collection 
Resolution range (Å) 
 
 
74.93-1.72 (1.76 –1.72) * 
Rmerge (%) 6.3 (74.3) 
I / σI 19.8 (3.4) 
Completeness (%) 100 (100) 
Redundancy 9.7 (9.7) 
 
Refinement 
 
Resolution (Å) 74.3-1.72 
No. reflections 42820 
Rwork / Rfree 17.62 / 19.51 
No. atoms  
    Protein 2362 
    ADP/Mg2+ 29 
    Water 197 
Mean B-factors  
    Protein 28.09 
    ADP/Mg2+ 19.16 
    Water 
Wilson B-factor 
37.17 
25.63 
r.m.s. deviations  
    bond lengths (Å) 0.005 
    bond angles (¡) 1.043 
 
MolProbity analysis 
 
All-atom clash-score 2.34 
Rotamers outliers (%) 0 
Ramachandran outliers (%) 0 
Ramachandran favoured (%) 97.25 
MolProbity score 1.15 
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